Su1026 Statin Use Reduces Risk of Progression of Liver Fibrosis, among Patients with Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial

Tracey G. Simon,Lindsay Y. King,Hui Zheng,Raymond T. Chung

DOI: https://doi.org/10.1016/s0016-5085(14)63517-4

IF: 29.4

2014-01-01

Gastroenterology

Abstract:BACKGROUND: Therapies that can slow the progression of liver fibrosis in chronic liver disease are needed.Mounting evidence suggests that statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, exert antiproliferative, antiangiogenic and anti-inflammatory effects on hepatic cells.Although animal models have demonstrated that statins effectively prevent progression of hepatic fibrosis, human data is lacking.AIM: We evaluated the effect of continuous statin use on histological liver fibrosis progression in the HALT-C Trial cohort.METHODS: Among the 1050 randomized subjects in the HALT-C cohort, 547 patients had non-cirrhotic hepatic fibrosis (Ishak Fibrosis Scores ≥ 3) and underwent serial liver biopsies at baseline, 1.5 years and 3.5 years after randomization.The primary histological outcome was defined as a 2-point or greater increase in Ishak fibrosis score on at least one of the two serial biopsies.We used complementary log-log regression analysis to assess the association between continuous statin use and time to histological progression.RESULTS: Thirty patients (5%) with non-cirrhotic hepatic fibrosis used statins continuously during the study observation period.Statin users were more likely to be African American, to have diabetes, and to have lower baseline alanine transferase (ALT) levels, when compared to non-users (Table 1).Continuous statin use was associated with a significantly decreased time to histological progression even after adjustment for body mass index, platelets, diabetes and hepatic steatosis score (HR 0.26, 95% CI 0.08 -0.84; p = 0.023).The mean change in Ishak fibrosis score for statin users was -0.33 (SE 0.18) during the 3.5 year observation period, while the mean change in Ishak fibrosis score among non-users was +0.43 (SE 0.07), p= 0.005 after adjustment for baseline fibrosis score.CONCLUSION: Statin use is associated with a significant reduction in fibrosis progression in advanced chronic hepatitis C infection.Randomized HALTC patients with baseline non-cirrhotic fibrosis (N=547) *Variables expressed as mean (+/-standard deviation) unless noted otherwise Su1027